Stay updated with breaking news from Nasdaq Repl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) fell 3.8% during trading on Wednesday . The company traded as low as $19.24 and last traded at $19.24. 16,801 shares changed hands during trading, a decline of 97% from the average session volume of 567,215 shares. The stock had previously closed at $20.00. Analyst Upgrades and Downgrades […]
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...
BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a...
A number of firms have modified their ratings and price targets on shares of Replimune Group (NASDAQ: REPL) recently: 5/25/2022 – Replimune Group was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes […]
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) – Analysts at Wedbush issued their FY2024 earnings per share estimates for shares of Replimune Group in a research note issued to investors on Tuesday, May 24th. Wedbush analyst R. Driscoll anticipates that the company will earn ($2.77) per share for the year. Wedbush currently has a “Outperform” […]